NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Childhood Myelodysplastic Syndromes
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Disseminated Neuroblastoma
Malignant Neoplasm

Interventions: Drug: ipilimumab
Drug: therapeutic allogeneic lymphocytes

First Posted Date: 2003-05-07

Last Posted Date: 2013-03-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00060372

Locations: 🇺🇸
Scripps Clinic - La Jolla, La Jolla, California, United States
🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸
Blood and Marrow Transplant Group of Georgia, Atlanta, Georgia, United States

and more 2 locations

Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer

Phase 2

Completed

Conditions: Recurrent Renal Cell Cancer
Stage III Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Drug: erlotinib hydrochloride
Other: laboratory biomarker analysis

First Posted Date: 2003-05-07

Last Posted Date: 2013-02-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00060307

Locations: 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States

APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Biological: bevacizumab
Biological: prostatic acid phosphatase-sargramostim fusion protein
Biological: sipuleucel-T
Biological: therapeutic autologous dendritic cells
Procedure: in vitro-treated peripheral blood stem cell transplantation

First Posted Date: 2003-05-07

Last Posted Date: 2013-02-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 25

Registration Number: NCT00027599

Locations: 🇺🇸
UCSF Comprehensive Cancer Center, San Francisco, California, United States

Voriconazole With or Without Interferon Gamma in Treating Patients With Aspergillosis or Other Fungal Infections

Phase 2

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Infection

First Posted Date: 2003-05-07

Last Posted Date: 2013-06-19

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00059878

Locations: 🇺🇸
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Shands Cancer Center at the University of Florida Health Science Center, Gainesville, Florida, United States
🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation

Not Applicable

Completed

Conditions: Cancer

First Posted Date: 2003-05-07

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00060021

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood

Phase 2

Completed

Conditions: Gastrointestinal Stromal Tumor
Recurrent Childhood Soft Tissue Sarcoma
Childhood Desmoplastic Small Round Cell Tumor
Lung Metastases
Recurrent Osteosarcoma
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Childhood Synovial Sarcoma
Recurrent Neuroblastoma

Interventions: Drug: imatinib mesylate
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2003-05-07

Last Posted Date: 2015-04-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 100

Registration Number: NCT00030667

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Immunotoxin in Treating Patients With Leukemia or Lymphoma

Phase 1

Completed

Conditions: Lymphoma
Leukemia

First Posted Date: 2003-05-06

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00002765

Locations: 🇺🇸
Laboratory of Molecular Biology, Bethesda, Maryland, United States
🇺🇸
Medicine Branch, Bethesda, Maryland, United States

LMB-9 Immunotoxin in Treating Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Colorectal Cancer
Lung Cancer
Pancreatic Cancer
Bladder Cancer
Esophageal Cancer
Gastric Cancer
Breast Cancer

First Posted Date: 2003-05-06

Last Posted Date: 2015-04-29

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00019435

Locations: 🇺🇸
Medicine Branch, Bethesda, Maryland, United States

SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer

Phase 1

Completed

Conditions: Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage III Colon Cancer
Stage III Rectal Cancer
Stage IV Colon Cancer
Stage IV Rectal Cancer

Interventions: Drug: irinotecan hydrochloride
Drug: semaxanib
Other: laboratory biomarker analysis

First Posted Date: 2003-05-05

Last Posted Date: 2013-01-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 68

Registration Number: NCT00005818

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Phase 3

Completed

Conditions: Kidney Cancer

First Posted Date: 2003-05-05

Last Posted Date: 2013-06-17

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00018941

Locations: 🇺🇸
Surgery Branch, Bethesda, Maryland, United States

Home Terms & Conditions Privacy Policy